scholarly journals Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic

Transfusion ◽  
2021 ◽  
Author(s):  
Gines Escolar ◽  
Maribel Diaz‐Ricart ◽  
Jeffrey McCullough
Keyword(s):  
Clinical Effectiveness ◽  
Platelet Concentrates ◽  
Pathogen Reduction

scholarly journals Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

2010 ◽  
pp. no-no ◽  
Author(s):  
Jean-Louis H. Kerkhoffs ◽  
Wim L. J. Van Putten ◽  
Viera M. J. Novotny ◽  
Peter A.W. Te Boekhorst ◽  
Martin R. Schipperus ◽  
...  
Keyword(s):  
Clinical Effectiveness ◽  
Platelet Concentrates ◽  
Pathogen Reduction ◽  
Additive Solution

scholarly journals Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light

2020 ◽  
Vol 7 ◽  
Author(s):  
Katarzyna I. Jankowska ◽  
Rana Nagarkatti ◽  
Nirmallya Acharyya ◽  
Neetu Dahiya ◽  
Caitlin F. Stewart ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Human Plasma ◽  
Blue Light ◽  
Chagas Disease ◽  
Light Treatment ◽  
Platelet Concentrates ◽  
Complete Inactivation ◽  
Pathogen Reduction ◽  
Biochemical Indices

The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal toward reducing the risk of transfusion-transmitted infectious diseases (TTIDs). We have previously demonstrated that 405 nm violet-blue light effectively reduces blood-borne bacteria in stored human plasma and platelet concentrates. In this report, we investigated the microbicidal effect of 405 nm light on one important bloodborne parasite Trypanosoma cruzi that causes Chagas disease in humans. Our results demonstrated that a light irradiance at 15 mWcm−2 for 5 h, equivalent to 270 Jcm−2, effectively inactivated T. cruzi by over 9.0 Log10, in plasma and platelets that were evaluated by a MK2 cell infectivity assay. Giemsa stained T. cruzi infected MK2 cells showed that the light-treated parasites in plasma and platelets were deficient in infecting MK2 cells and did not differentiate further into intracellular amastigotes unlike the untreated parasites. The light-treated and untreated parasite samples were then evaluated for any residual infectivity by injecting the treated parasites into Swiss Webster mice, which did not develop infection even after the animals were immunosuppressed, further demonstrating that the light treatment was completely effective for inactivation of the parasite; the light-treated platelets had similar in vitro metabolic and biochemical indices to that of untreated platelets. Overall, these results provide a proof of concept toward developing 405 nm light treatment as a pathogen reduction technology (PRT) to enhance the safety of stored human plasma and platelet concentrates from bloodborne T. cruzi, which causes Chagas disease.

scholarly journals A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology

Platelets ◽  
2018 ◽  
Vol 30 (3) ◽  
pp. 368-379 ◽  
Author(s):  
Vishal Salunkhe ◽  
Iris M. De Cuyper ◽  
Petros Papadopoulos ◽  
Pieter F. van der Meer ◽  
Brunette B. Daal ◽  
...  
Keyword(s):  
Storage Time ◽  
Platelet Concentrates ◽  
Proteomics Study ◽  
Platelet Proteome ◽  
Pathogen Reduction

scholarly journals Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela

2016 ◽  
Vol 44 (1) ◽  
pp. 5-9 ◽  
Author(s):  
M. Dolores Vilariño ◽  
Azucena Castrillo ◽  
Alfredo Campos ◽  
Rachel Kilian ◽  
Mercedes Villamayor ◽  
...  
Keyword(s):  
Clinical Performance ◽  
Platelet Concentrates ◽  
Santiago De Compostela ◽  
Pathogen Reduction

Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates

Transfusion ◽  
2013 ◽  
Vol 54 (3) ◽  
pp. 577-584 ◽  
Author(s):  
Yen S. Loh ◽  
Lacey Johnson ◽  
Matthew Kwok ◽  
Denese C. Marks
Keyword(s):  
Buffy Coat ◽  
Platelet Concentrates ◽  
Reduction Treatment ◽  
Immunomodulatory Capacity ◽  
Pathogen Reduction

Treatment of platelet concentrates with ultraviolet C light for pathogen reduction increases cytokine accumulation

Transfusion ◽  
2016 ◽  
Vol 56 (6) ◽  
pp. 1377-1383 ◽  
Author(s):  
Per Sandgren ◽  
Gösta Berlin ◽  
Nahreen Tynngård
Keyword(s):  
Platelet Concentrates ◽  
Ultraviolet C ◽  
Pathogen Reduction

Lymphocyte Survival and Activation in Stored Platelet Concentrates After Gamma-Irradiation or Pathogen Reduction Technology Treatment.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2113-2113
Author(s):  
Jolanta J Wozniak ◽  
Agnieszka Krzywdzinska ◽  
Elzbieta Lachert ◽  
Karolina Janik ◽  
Jolanta Antoniewicz-Papis ◽  
...  
Keyword(s):  
Gamma Irradiation ◽  
Conflicts Of Interest ◽  
Lymphocyte Activation ◽  
Equal Weight ◽  
Ratio Test ◽  
Blood Products ◽  
Platelet Concentrates ◽  
Becton Dickinson ◽  
Lymphocyte Survival ◽  
Pathogen Reduction

Abstract Abstract 2113 Poster Board II-90 The presence of white blood cells, particularly lymphocytes, in blood products has been shown to contribute to the development of a variety of adverse events including both donor anti-recipient and recipient anti-donor responses. Therefore leukoreduction of blood products or inactivation of leukocytes is necessary. We are currently using gamma-irradiation (Radiator Gammacell 3000 Elan) to inactivate leukocytes in blood components. This study shows the comparison of irradiation and PRT treatment (Mirasol*®) on lymphocyte survival and inactivation in non-leukoreduced platelet concentrates (PCs). PRT treatment is a pathogen reduction technology that targets nucleic acids after exposure to riboflavin and UV-light. We analyzed 7 untreated (C), 7 PRT treated (M) and 7 irradiated PCs (RD) in our study. Non-leukoreduced buffy coats (mean volume 65 ml) were obtained from the Regional Blood Center, Warsaw. PCs were prepared by pooling 15 buffy coats (ABO identical) suspended in 3 plasma units, and dividing the pool into 3 equal-weight units in bags made of the same material. Following addition of 35 ml of riboflavin solution, M units were illuminated. The same volume of saline solution, was added to the C group and RD units. All PCs were then stored at 22°C with agitation for 5 days. Samples were removed on days 1, 3 and 6 for analysis. The lymphocyte survival rate was determined by 7AAD (7-amino-actinomycin D staining of dead cells, Becton Dickinson) and their activation by anti-CD69-APC staining (Becton Dickinson). Samples were also stained with anti-CD45-PE antibodies to identify and gate on lymphocytes. Samples were analyzed on the Becton Dickinson Cytometer FACSCanto I. No increase in the number of dead cells was observed during 6 days of storage in the C group. After 3 days of storage however, in the M group the percentage of dead cells was significant higher than in C and RD groups (Student t-test, p=0.004 and p=0.03, respectively). After 6 days, the percentage of dead cells in the M samples was 72% vs. 30% following irradiation. The percentage of 7AAD-positive cells was significantly higher compare to C samples, both in M (p=0,001) and in RD samples (p=0,004). The percentage of dead lymphocytes was also observed to be statistically higher in M samples than in RD (p= 0,001). Analysis of lymphocyte activation was performed on live (7AAD-negative, CD45-positive) cells only. CD69 expression ranged between 20% and 40% in all tested samples (C, M, RD) during 6 days of storage. On days 1 and 3 of storage, Mirasol treatment significantly reduced lymphocyte activation as shown by the ratio (test/control) of %CD69-positive cells (p=0,004 and p=0,001, respectively) and mean fluorescence expression intensity of CD69. Interestingly, after 6 days of storage, RD samples showed significant higher lymphocyte activation then C and M samples (p=0,03 and p=0,02, respectively). In summary, a significant increase of dead lymphocytes after 6 days of storage was observed in PRT-treated PCs. This increase was two-fold higher than in gamma-irradiated PCs. At the same time a decrease in lymphocyte activation during 6 days of storage was observed in PRT-treated PCs. Overall, the use of PRT achieves better leukocyte inactivation than gamma-irradiation. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document